ENO2 and neoplasm: Further comparison of the Septin9, Epo, and MT-1A MDM panel with conventional tumor markers in diagnosing different tumor stages in the clinical cohort showed positive detection rates of 56.25%, 77.36%, 86.49%, 89.71%, and 94.02% for cancer stages 0–IV, respectively, which were notably higher than those of the conventional tumor markers CEA, SCC, CA199, and NSE (Figure 5A and Supplemental Figure 6).